---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-013207"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2024-10-09T23:59:59+00:00"
generated_at: "2026-05-30T17:07:03.540071+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Capricor initiates rolling BLA submission to FDA for deramiocel in DMD cardiomyopathy

## Summary
- Rolling submission started Oct 9, 2024; plans to complete by end of 2024.
- BLA seeks full approval for deramiocel to treat all DMD cardiomyopathy patients.
- No approved treatments currently exist for DMD cardiomyopathy.
- Application may be eligible for priority review by FDA.

## SEC filing metadata
- accession: 0001558370-24-013207
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2024-10-09T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837024013207/0001558370-24-013207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837024013207/capr-20241009x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-013207
- JSON: https://secwatch.observer/filing/0001558370-24-013207.json
- Plain text: https://secwatch.observer/filing/0001558370-24-013207.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.